News - Biotechnology
'Lack of resources inhibiting growth of biotechnology sector'
23 January 2013
ISLAMABAD - The biotechnology sector has not been developed to its full potential because of limited sources, inadequate stock of trained manpower and lack of proper coordination among institutions. The cross cutting field of biotechnology has ...
Click on the link to read the full article at PakistanToday.com.pk (This link will open in a new window)6 Biotechnology Stocks to Sell Now
23 January 2013
Oncothyreon (NASDAQ:ONTY) experiences a ratings drop this week, going from last week's D to an F. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F's in Earnings Growth, Equity, and ...
Click on the link to read the full article at Investorplace.com (This link will open in a new window)Biotechnology industry Roundup, stocks under investors list (ARNA, AMGN ...
22 January 2013
The Biotechnology industry was also in the red after painted by steep losses from Arena Pharmaceuticals (NASDAQ:ARNA), Amgen Inc. (NASDAQ:AMGN) and Dendreon Corp. (NASDAQ:DNDN), as these stocks also led the most active biotech stocks for the ...
Click on the link to read the full article at The Point (This link will open in a new window)What Makes For A Market Leading Return In Biotechnology?
22 January 2013
What is it that produces the best gains in biotechnology? If you look back on companies such as Pharmacyclics (PCYC) and Jazz Pharmaceuticals (JAZZ) you will see a history of massive returns in a short period of time, which began during the clinical ...
Click on the link to read the full article at Seeking Alpha (This link will open in a new window)World's Largest Biotechnology Company Uses Team of 74 Lobbyists to Win ...
22 January 2013
Amgen, Inc., the world's largest biotechnology firm, will continue to sell one of its best selling drugs at unregulated prices, thanks to a provision buried within the fiscal-cliff compromise. With the help of its corps of 74 lobbyists, Amgen convinced ...
Click on the link to read the full article at AllGov (This link will open in a new window)ADC Biotechnology secures
22 January 2013
Anti-cancer drug developer ADC Biotechnology has received a funding package worth
Click on the link to read the full article at Insider Media (This link will open in a new window)RHODES UNIVERSITY: Biotechnology unit 'surprises with its skills'
21 January 2013
THE danger for South Africa is that we are in competition with everyone in the world of biotechnology, says Janice Limson, head of Rhodes University's biotechnology unit. "But the thing with innovation is that a hit can come from anywhere." The ...
Click on the link to read the full article at BDlive (This link will open in a new window)UN biotechnology institute seeks govt takeover
18 January 2013
International Centre for Genetic Engineering and Biotechnology started as a UN Industrial Development Organisation project in 1987 and later became a full fledged UN centre in Delhi since 1994 with the objective of translating western biotechnology ...
Click on the link to read the full article at Deccan Herald (This link will open in a new window)BLOOMAGE BIOTECHNOLOGY CORPORATION LTD : Announcements and ...
18 January 2013
The Board announces that on 18 January 2013, Bloomage Hyinc and Bloomage Property entered into the Termination Agreement I and the Termination Agreement II, pursuant to which the parties agreed to terminate the lease for Property A with effect from 30 ...
Click on the link to read the full article at 4-traders (This link will open in a new window)Genetech Biotechnology Corp. (OTC:GNBT) Recovers Lost Ground
18 January 2013
2 Comments. Watch the video to learn about the probability of Generex Biotechnology Corp. (GNBT) Chart Signal as of Jan 19 2013. Get Adobe Flash player. This free program will calculate the probabilities of Generex Biotechnology Corp. (GNBT) stock ...
Click on the link to read the full article at HotStocked (This link will open in a new window)
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
